5. |
- Pettersson, Olof, 1986-, et al.
(author)
-
Tumor Growth Rate in Pancreatic Neuroendocrine Tumor patients undergoing systemic therapies
-
Other publication (other academic/artistic)abstract
- Background: Therapy monitoring in Pancreatic Neuroendocrine Tumor (PanNET) patients undergoing systemic therapies is difficult as reliable clinical, radiological and biochemical markers have been difficult to establish. Ki-67 index is considered a reliable marker of tumor burden. Tumor growth rate (TGR) allows for quantitative assessment of the tumor kinetics expressed %/Months. We investigated TGR in PanNET patients with increased versus stable Ki-67, between at least two tissue specimens. Methods: Patients were screened for inclusion from a previously described cohort of PanNET patients (n=46) treated between 1980 and 2016 at Uppsala University Hospital, with sporadic disease and Ki-67 acquired at least twice during the disease course. Inclusion criteria were at least two contrast-enhanced computer tomographies (CECT) of adequate quality during the course of the treatment and at least one lesion discernible by CECT. Mann-Whitney U test was carried out to test for differences between the groups. Results: In twenty-one patients, there was a grade increase and a mean TGR of 0.56 %/Months (SD 30.70; range -277.04, 317.35).In fourteen patients, there was no grade increase and a mean TGR of -0.26 %/Months (SD 14.14; range -76.01, 88.96). There was no significant difference in TGR between the patients that increased in grade versus the patients that did not increase in grade between the biopsies (p=0.29, 95% CI -1.79, 0.52, n=35). Conclusion: TGR was numerically but not significantly higher in patients that increased compared to patients that did not increase in grade between the biopsies.
|
|